UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2022.

 

Commission File Number: 000-53805

 

Intellipharmaceutics International Inc.

(Translation of registrant’s name into English)

   

30 WORCESTER ROAD TORONTO, ON M9W 5X2

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒    Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

This Report of Foreign Private Issuer on Form 6-K and the attached exhibits 23.1, 99.1, 99.2 and 101 shall be incorporated by reference into the Company’s effective Registration Statements on Form F-3, as amended and supplemented (Registration Statement Nos. 333-172796 and 333-218297), filed with the Securities and Exchange Commission, from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by Intellipharmaceutics International Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934.

 

 

 

   

EXHIBIT LIST

 

Exhibit

 

Description 

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm (MNP LLP)

 

 

 

99.1

 

Management Discussion and Analysis of Financial Condition and Results of Operations for the Year Ended November 30, 2021

 

 

 

99.2

 

Consolidated Financial Statements and Notes to Consolidated Financial Statements of Intellipharmaceutics International Inc. for the Year Ended November 30, 2021

 

 

 

99.3

 

News Release dated February 28, 2022 - Intellipharmaceutics Announces 2021 Year End Results

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Intellipharmaceutics International Inc.

 

 

(Registrant)

 

 

 

 

Date: February 28, 2022

/s/ Amina Odidi

 

 

Amina Odidi

 

 

 

 

 

Acting Chief Financial Officer and President

 

 

 

3

 

IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos IntelliPharmaCeutics (CE).
IntelliPharmaCeutics (CE) (USOTC:IPCIF)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos IntelliPharmaCeutics (CE).